Novocure announced today the agenda for the company's research and development day for analysts and investors, which will begin at 1 p.m. EST on Monday, Dec. 12, 2016, in New York City. The event will feature four speakers from Novocure and three external medical experts who will provide analyses from completed clinical trials, including the full, 695-patient trial cohort from the EF-14 phase 3 pivotal trial in newly diagnosed glioblastoma , new data from the PANOVA phase 2 pilot trial in advanced pancreatic cancer, new data from the INNOVATE phase 2 pilot trial in recurrent ovarian cancer, and interim data from the STELLAR phase 2 pilot trial in mesothelioma.
